Citation Impact
Citing Papers
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
2000 Standout
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
2013 StandoutScience
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
2009 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Transplantation ofex vivoexpanded endothelial progenitor cells for therapeutic neovascularization
2000 Standout
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/ protein and vascular endothelial growth factor
2002
Next-generation proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis
2016
The relationship between prognostic and predictive factors in the management of breast cancer
1998
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
2012 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
2006 Standout
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications
2001
Breast cancer
2016 Standout
Oxidative stress, inflammation, and cancer: How are they linked?
2010 Standout
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
2016 Standout
Forces in Tissue Morphogenesis and Patterning
2013 Standout
Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma
1999
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
2005
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Paclitaxel (Taxol)
1995 Standout
The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease
2003
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Strength Dependence of Cadherin-Mediated Adhesions
2010
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Synthetic organic dyes as contaminants of the aquatic environment and their implications for ecosystems: A review
2020 Standout
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
2011 Standout
High D ‐dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes
2006
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Advances in the Treatment of Malignant Pleural Mesothelioma
1999
Role of Hypoxia-Inducible Factor 1 in Gastric Cancer Cell Growth, Angiogenesis, and Vessel Maturation
2004 StandoutNobel
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma
1993
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer.
1994
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
1995
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293
1996
IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
1997 Standout
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Chemotherapy for Malignant Pleural Mesothelioma
2003
Acute tumor lysis syndrome in solid tumors—a case report and review of the literature
2003
Phase II study of weekly docetaxel in patients with metastatic breast cancer
2002
VEGF-targeted therapy: mechanisms of anti-tumour activity
2008 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Targeting autophagy in cancer
2017 Standout
A Review of Chemotherapy Trials for Malignant Mesothelioma
1998
Molecular mechanisms of metastasis in breast cancer—clinical applications
2010
Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients
2012
Soluble endoglin contributes to the pathogenesis of preeclampsia
2006 Standout
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Gold nanoparticles in biomedical applications: recent advances and perspectives
2011 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer
2000
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Advances in Malignant Mesothelioma
2005 Standout
Stroke in patients with cancer
2004
Docetaxel: Standard Recommended Dose of 100 mg/m2 Is Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With Chemotherapy—A Phase II Single-Center Study
1999
High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer.
2002
The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
2003
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
2000
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES
1999
Circulating Tumor Cells in Breast Cancer: Detection Systems, Molecular Characterization, and Future Challenges
2012
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
2008 Standout
Tumour vasculature as a target for anticancer therapy
2000
The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer
2002 StandoutNobel
Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi‐row detector computed tomography scanning
2010
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
Circulating Tumor Cells in Breast Cancer:Detection Systems, Molecular Characterization, and Future Challenges
2011
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
2001
Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo
1998
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
CHS 828 Inhibits Neuroblastoma Growth in Mice Alone and in Combination with Antiangiogenic Drugs
2002
Simple and rapid colorimetric detection of melanoma circulating tumor cells using bifunctional magnetic nanoparticles
2017
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
1997
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer.
2000
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Vascular Endothelial Growth Factor Inhibits the Development of Dendritic Cells and Dramatically Affects the Differentiation of Multiple Hematopoietic Lineages In Vivo
1998
Signal relays in the VEGF system
1999
Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
1999
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
2021 Standout
Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
2000
Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line.
2000
Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.
2003
Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
2011
Works of A. Prové being referenced
Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer
2002
Coping with toxicities of docetaxel (TaxotereTM)
1993
Tumor lysis syndrome in a patient with metastatic merkel cell carcinoma
1991
Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer
2009
Inflammatory breast cancer: current understanding
2006
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma
1994
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature
2000
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
1997
A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer
1994
Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence
2008
A Phase II Study of the Combination of Endocrine Treatment and Bortezomib in Patients with Endocrine Resistant Metastatic Breast Cancer.
2009